Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9477	Companies
185475	Keywords
117817	Articles
99317	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/30/2025 at 06:30, 1 month 6 days ago

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
BRIEF

published on 10/21/2025 at 06:35, 1 month 15 days ago

Formycon lance le premier biosimilaire du ranibizumab en seringue préremplie en Europe

Teva Pharmaceuticals FYB201/Ranivisio® Biosimilaire Du Ranibizumab Seringue Préremplie Lancement De Formycon
BRIEF

published on 10/21/2025 at 06:35, 1 month 15 days ago

Formycon Launches Europe’s First Ranibizumab Biosimilar in Pre-filled Syringe

Teva Pharmaceuticals Ranibizumab Biosimilar Pre-filled Syringe FYB201/Ranivisio® Formycon Launch
PRESS RELEASE

published on 10/21/2025 at 06:30, 1 month 15 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 1 month 20 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
BRIEF

published on 10/16/2025 at 06:35, 1 month 20 days ago

Actor Pharmaceuticals et Megalabs s'associent pour la commercialisation du FYB203

Formycon AG Biosimilaire Eylea® Megalabs Acteur Pharmaceutique Commercialisation Du FYB203
PRESS RELEASE

published on 10/16/2025 at 06:30, 1 month 20 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF

published on 10/02/2025 at 06:35, 2 months 3 days ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
BRIEF

published on 10/02/2025 at 06:35, 2 months 3 days ago

Formycon obtient une licence américaine pour le biosimilaire d'Aflibercept

Formycon AG Lancement Sur Le Marché Américain Biosimilaire D'Aflibercept Accord Regeneron Résolution Des Litiges En Matière De Brevets
PRESS RELEASE

published on 10/02/2025 at 06:30, 2 months 3 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes

Accesswire

Published on 12/05/2025 at 14:00, 31 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 31 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 11 hours 56 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 12 hours 1 minute ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 13 hours 31 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 14:22, 9 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 14 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 21 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 46 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 1 hour 31 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting

Les Echos

Published on 12/05/2025 at 13:58, 33 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 5 hours 46 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 5 hours 46 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 5 hours 49 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 20 hours 16 minutes ago

Résiliation d'une convention conclue entre actionnaires

View all LES ECHOS COMFI WIRE